MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'Roche Investor Update' source. Sat, 20 Mar 2010 15:04:18 +0100 http://www.medworm.com/index.php?rid=3376457&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-03-18.htm Leading late-stage pipeline and innovation strategy presented at investor conference. Roche is set to strengthen its global leadership position in oncology and to expand in therapeutic areas such as metabolism, inflammation and diseases of the central nervous system. At its first investor conference following the successful integration of Roche and Genentech, the company highlighted its vision and the strategy that it intends to pursue in order to ensure a stable flow of novel medicines from its rich development pipeline. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3376457 Thu, 18 Mar 2010 06:00:00 +0100 3376457 http://www.medworm.com/index.php?rid=3372420&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-03-17.htm Roche announced today that it has submitted a supplemental Biologics License Application (sBLA) to the United States (US) Food and Drug Administration (FDA) for ACTEMRA (tocilizumab, RoACTEMRA in the European Union) for the prevention of structural joint damage and to improve physical function in adults with moderately to severe active rheumatoid arthritis (RA). ACTEMRA was approved by the FDA on January 8, 2010 as the first interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody to treat RA in adult patients after an inadequate response to at least one other medicine called a tumor necrosis factor (TNF) antagonist. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3372420 Wed, 17 Mar 2010 06:00:00 +0100 3372420 http://www.medworm.com/index.php?rid=3365098&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-03-15.htm Roche will publish its Sales Results for the 1st Quarter of 2010 prior to the opening of the Swiss Stock Exchange on Thursday April 15th, 2010. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3365098 Mon, 15 Mar 2010 09:00:00 +0100 3365098 http://www.medworm.com/index.php?rid=3356883&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-03-12.htm Roche announced today the topline results of a phase III trial led by the US Cancer and Leukemia Group B (CALGB) and sponsored by the National Cancer Institute investigating the use of Avastin (bevacizumab) in combination with docetaxel chemotherapy and prednisone in men with late stage prostate cancer (hormone-refractory / HRPC). The study, known as CALGB 90401, did not meet its primary objective of extending overall survival compared to chemotherapy and prednisone alone. A preliminary assessment of safety performed by CALGB has shown adverse events that have been previously observed in pivotal trials with Avastin. Data from the study will be submitted by CALGB for presentation at the 2010 American Society of Clinical Oncology (ASCO) annual meeting, June 4 to 8, 2010. (Source: Roche Inves... Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3356883 Fri, 12 Mar 2010 06:00:00 +0100 3356883 http://www.medworm.com/index.php?rid=3341014&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-03-08.htm Roche and Biogen Idec announced today their decision to suspend Ocrelizumab treatment of patients in the Rheumatoid Arthritis (RA) programme. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3341014 Mon, 08 Mar 2010 06:00:00 +0100 3341014 http://www.medworm.com/index.php?rid=3320450&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-03-02.htm Roche's Annual General Meeting, which was held today in Basel, has approved all the Board of Directors' proposals. The 698 shareholders in attendance, representing 143,055,648, or 89.4% of a total of 160,000,000 bearer shares, approved the 2009 Annual Report and financial statements. They also authorised a +20% increase in the dividend to 6.00 Swiss francs per share and non-voting equity. With this increase, the payout ratio rises to 53%, which means that about half of net income will be paid out to shareholders. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3320450 Tue, 02 Mar 2010 12:30:00 +0100 3320450 http://www.medworm.com/index.php?rid=3304810&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-02-25.htm Roche announced today that a phase III study showed the combination of Avastin (bevacizumab) and chemotherapy followed by maintenance use of Avastin increased the time women with advanced ovarian cancer lived without their disease worsening (progression-free survival or PFS) compared to chemotherapy alone. A preliminary assessment of safety noted adverse events previously observed in pivotal trials with Avastin. Data from the study will be submitted for presentation at the 2010 American Society of Clinical Oncology (ASCO) annual meeting, June 4 to 8, 2010. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3304810 Thu, 25 Feb 2010 06:00:00 +0100 3304810 http://www.medworm.com/index.php?rid=3300400&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-02-24.htm Roche announced today that Xeloda (capecitabine) in combination with oxaliplatin (a combination known as XELOX) has been recommended by the Committee on Human Medicinal Products (CHMP) for the adjuvant (post-surgery) treatment of patients with early colon cancer. The CHMP positive recommendation was based on results from the phase III pivotal NO16968 (XELOXA) study, one of the largest studies of patients with stage III (early) colon cancer, which showed that patients taking XELOX immediately after surgery lived disease-free for longer compared to those treated with the chemotherapy regimen 5-fluorouracil/leucovorin (5-FU/LV). (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3300400 Wed, 24 Feb 2010 06:00:00 +0100 3300400 http://www.medworm.com/index.php?rid=3296769&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-02-23.htm Roche announced today the topline results from a global phase III trial investigating the use of Avastin (bevacizumab) in combination with Xeloda (capecitabine) or fluorouracil and cisplatin chemotherapy in patients with inoperable, advanced or metastatic gastric cancer (stomach cancer). The study, known as AVAGAST, did not meet its primary endpoint of extending overall survival in patients treated with Avastin in combination with chemotherapy compared to the same chemotherapy plus placebo. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3296769 Tue, 23 Feb 2010 06:00:00 +0100 3296769 http://www.medworm.com/index.php?rid=3296770&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-02-19.htm Roche announced today that the US Food and Drug Administration (FDA) approved Rituxan/MabThera (rituximab) plus fludarabine and cyclophosphamide (FC) chemotherapy for people with either previously untreated (first-line) or previously treated (relapsed or refractory) CD20-positive chronic lymphocytic leukemia (CLL). (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3296770 Fri, 19 Feb 2010 06:00:00 +0100 3296770 http://www.medworm.com/index.php?rid=3296771&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-02-03.htm Record sales, double-digit growth in operating profit and Core Earnings per share – Dividend increase by 20% to 6.00 Swiss francs proposed - Group sales increase by 10% to 49.1 billion Swiss francs (8% in Swiss francs, 7% in US dollars). Both divisions gain market share. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3296771 Wed, 03 Feb 2010 06:00:00 +0100 3296771 http://www.medworm.com/index.php?rid=3296773&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-01-28b.htm Roche announced today that it will enter into a strategic alliance with Singapore’s scientific and medical institutions to set up a major new translational research hub in Singapore. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3296773 Thu, 28 Jan 2010 06:00:00 +0100 3296773 http://www.medworm.com/index.php?rid=3296772&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-01-28.htm Roche announced today that the European Commission has approved Herceptin (trastuzumab) in combination with chemotherapy for use in patients with HER2-positive metastatic stomach (gastric) cancer. The approval is based on the impressive results from the international ToGA trial, which showed that treatment with Herceptin significantly prolongs the lives of patients with this aggressive cancer. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3296772 Thu, 28 Jan 2010 06:00:00 +0100 3296772 http://www.medworm.com/index.php?rid=3214790&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2010-01-28b.htm Roche announced today that it will enter into a strategic alliance with Singapore’s scientific and medical institutions to set up a major new translational research hub in Singapore. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3214790 Thu, 28 Jan 2010 06:00:00 +0100 3214790 http://www.medworm.com/index.php?rid=3214789&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2010-01-28.htm Roche announced today that the European Commission has approved Herceptin (trastuzumab) in combination with chemotherapy for use in patients with HER2-positive metastatic stomach (gastric) cancer. The approval is based on the impressive results from the international ToGA trial, which showed that treatment with Herceptin significantly prolongs the lives of patients with this aggressive cancer. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3214789 Thu, 28 Jan 2010 06:00:00 +0100 3214789 http://www.medworm.com/index.php?rid=3296774&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-01-27.htm Roche will publish its Full Year Results for 2009 prior to the opening of the Swiss Stock Exchange on February 3 at 7:00 CET / 6:00 GMT / 1:00 AM EST. Concurrently, the Full Year Presentation Slides and the Full Year Report will be available on te website http://ir.roche.com. We would like to invite all interested parties to dial in or participate in any of the scheduled events outlined below: 3 February; 8:00 CET – Morning Telephone Conference - 3 February; 15:00 GMT - Presentation in London (16:00 CET) - 5 February; 12:30 PM EST – Presentation in New York (18:30 CET) (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3296774 Wed, 27 Jan 2010 09:00:00 +0100 3296774 http://www.medworm.com/index.php?rid=3296775&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-01-04.htm Roche will publish its Full Year Results for 2009 prior to the opening of the Swiss Stock Exchange on February 3 at 7:00 CET / 6:00 GMT / 1:00 AM EST. Concurrently, the Full Year Presentation Slides and the Full Year Report will be available on te website http://ir.roche.com. We would like to invite all interested parties to dial in or participate in any of the scheduled events outlined below: 3 February; 8:00 CET – Morning Telephone Conference - 3 February; 15:00 GMT - Presentation in London (16:00 CET) - 5 February; 12:30 PM EST – Presentation in New York (18:30 CET) (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3296775 Mon, 04 Jan 2010 09:00:00 +0100 3296775 http://www.medworm.com/index.php?rid=3138379&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2010-01-04.htm Roche will publish its Full Year Results for 2009 prior to the opening of the Swiss Stock Exchange on February 3 at 7:00 CET / 6:00 GMT / 1:00 AM EST. Concurrently, the Full Year Presentation Slides and the Full Year Report will be available on te website http://ir.roche.com. We would like to invite all interested parties to dial in or participate in any of the scheduled events outlined below: 3 February; 8:00 CET – Morning Telephone Conference - 3 February; 15:00 GMT - Presentation in London (16:00 CET) - 5 February; 12:30 PM EST – Presentation in New York (18:30 CET) (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3138379 Mon, 04 Jan 2010 09:00:00 +0100 3138379 http://www.medworm.com/index.php?rid=3296776&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2010-01-04b.htm Roche announced today that it has submitted an application to the European Medicines Agency (EMEA) to extend the label of Xeloda (capecitabine) for use in combination with oxaliplatin (XELOX) in the adjuvant (post-surgery) treatment of patients with early colon cancer. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3296776 Mon, 04 Jan 2010 06:00:00 +0100 3296776 http://www.medworm.com/index.php?rid=3296777&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Finvestors%2Fir_update%2Finv-update-2009-12-22.htm Genentech, Inc., a wholly owned member of the Roche Group, today announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Lucentis (ranibizumab injection) for patients with macular edema following retinal vein occlusion (RVO). (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3296777 Tue, 22 Dec 2009 07:45:00 +0100 3296777 http://www.medworm.com/index.php?rid=3103525&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-12-18b.htm Dr Severin Schwan (CEO Roche Group) and the Roche Investor Relations team would like to invite you to the first Investor meeting since the integration of Roche and Genentech, to be held on Thursday 18 March 2010 in New York. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3103525 Fri, 18 Dec 2009 14:42:00 +0100 3103525 http://www.medworm.com/index.php?rid=3098738&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-12-18.htm Roche announced today that the European Medicines Agency (EMEA) Committee on Human Medicinal Products (CHMP) has issued a positive recommendation for the use of Herceptin (trastuzumab) in combination with standard chemotherapy for the treatment of patients with HER2-positive metastatic stomach (gastric) cancer (metastatic adenocarcinoma of the stomach or gastro-esophageal junction). (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3098738 Fri, 18 Dec 2009 12:45:00 +0100 3098738 http://www.medworm.com/index.php?rid=3094717&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-12-17b.htm Taspoglutide demonstrates non-inferiority HbA1c change versus insulin glargine and superiority in HbA1c change versus placebo (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3094717 Thu, 17 Dec 2009 06:00:00 +0100 3094717 http://www.medworm.com/index.php?rid=3083758&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-12-14b.htm Roche has been informed that the U.S. Food and Drug Administration (FDA) is allowing enrolment to resume into a phase III clinical trial (E5103) evaluating Avastin in combination with anthracycline, cyclophosphamide and paclitaxel chemotherapy in women with early-stage HER2-negative breast cancer. E5103 is sponspored by the National Cancer Institute (NCI) under a Cooperative Research and Development Agreement between the NCI and Genentech, a wholly-owned member of the Roche Group, and is being conducted by a network of researchers led by the Eastern Cooperative Oncology Group (ECOG). (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3083758 Mon, 14 Dec 2009 06:00:00 +0100 3083758 http://www.medworm.com/index.php?rid=3083757&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-12-14.htm Roche announced new long-term follow up-data from two large pivotal studies evaluating adjuvant Herceptin in HER2-positive early- stage breast cancer presented this weekend at the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS). Both studies, N9831 conducted by the North Central Cancer Treatment Group (NCCTG) and BCIRG006 performed by the Breast Cancer International Research Group consistently showed that Herceptin reduced the risk of the cancer returning by about one third in women with HER2-positive early breast cancer compared to patients receiving chemotherapy alone. In both studies, at least 80% of women receiving one year of Herceptin were alive free of the disease at 5 years follow-up. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3083757 Mon, 14 Dec 2009 06:00:00 +0100 3083757 http://www.medworm.com/index.php?rid=3081424&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-12-12b.htm Roche today announced positive results from a Phase II study of trastuzumab-DM1 (T-DM1). As assessed by independent review, T-DM1 shrank the tumors (also known as objective response) in 33 percent of women with advanced (metastatic) HER2-positive breast cancer that had worsened following previous treatment. Women in the study had already received an average of seven drugs for metastatic disease, including chemotherapy, trastuzumab and lapatinib, prior to receiving T-DM1. No new or unexpected safety signals were observed. Results were presented today at the 32nd Annual San Antonio Breast Cancer Symposium (Abstract #710). (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3081424 Sat, 12 Dec 2009 13:00:00 +0100 3081424 http://www.medworm.com/index.php?rid=3081425&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-12-11.htm Roche today announced results from a phase III study (RIBBON 2) of Avastin® (bevacizumab) in women with advanced HER2-negative breast cancer who had previously received chemotherapy as first-line treatment. The study showed that women who received Avastin in combination with commonly used chemotherapies as second-line treatment had a 28% improvement in the chance of being alive without the disease getting worse (progression-free survival or PFS) compared to chemotherapy alone. Adverse events were consistent with those previously reported for Avastin and no new Avastin safety findings were observed in the study. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3081425 Fri, 11 Dec 2009 18:30:00 +0100 3081425 http://www.medworm.com/index.php?rid=3081426&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-12-11b.htm Roche, Genentech, Inc. a wholly owned member of the Roche Group, and Biogen Idec announced today a Phase III study (STAGE) of the investigational humanized anti-CD20 monoclonal antibody ocrelizumab given in combination with methotrexate (MTX) met its primary endpoint of improving signs and symptoms (as measured by American College of Rheumatology or ACR20 response) in rheumatoid arthritis (RA) patients who had an inadequate response to MTX at both 24 and 48 weeks. The companies continue to analyze the study results and plan to submit the data for presentation at an upcoming medical meeting. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3081426 Fri, 11 Dec 2009 17:00:00 +0100 3081426 http://www.medworm.com/index.php?rid=3077726&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-12-11c.htm Further analysis could promote new paradigm in the management of heart failure. Roche and study investigators at the Massachusetts General Hospital have announced today that active enrollment into the Pro-BNP Outpatient Tailored Congestive Heart Failure Therapy (PROTECT) study (Clinical Trials.gov identifier: NCT00351390) has been stopped early based on a positive interim analysis. PROTECT, a prospective randomized trial comparing a strategy of aggressive heart failure therapy guided by levels of a cardiac hormone—amino-terminal pro-B type natriuretic peptide (NT-proBNP)—versus standard heart failure treatment without NT-proBNP guidance has been enrolling subjects in the Heart Center at the Massachusetts General Hospital since 2006. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3077726 Fri, 11 Dec 2009 06:00:00 +0100 3077726 http://www.medworm.com/index.php?rid=3073769&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-12-09b.htm Roche Molecular Systems, Inc. announced today the launch of a new clinical laboratory system designed to increase laboratory testing efficiency and to accommodate current and long-term molecular diagnostic needs. The cobas® 4800 System combines CE-marked in vitro diagnostic tests for Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG) and human papillomavirus (HPV) testing with fully-automated sample preparation and real-time polymerase chain reaction (PCR) technology. The tests are designed to detect the 14 HPV high-risk genotypes widely accepted to cause cervical cancer and bacterial DNA associated with chlamydia and gonorrhea infections. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3073769 Wed, 09 Dec 2009 17:00:00 +0100 3073769 http://www.medworm.com/index.php?rid=3069402&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-12-09.htm Roche announced today that new 5 year follow-up data from two pivotal studies with Herceptin® (trastuzumab) in early breast cancer; key results from a study of Avastin® (bevacizumab) in the second-line treatment of advanced breast cancer and strong data on the use of trastuzumab-DM1 (T-DM1), the first antibody-drug conjugate in development for very advanced HER2-positive breast cancer, will all be presented during the CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) from 9 to 13 December 2009. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3069402 Wed, 09 Dec 2009 06:00:00 +0100 3069402 http://www.medworm.com/index.php?rid=3065471&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-12-08.htm Roche announced today at the 51st Meeting of the American Society of Hematology (ASH) in New Orleans, LA (USA) that the pivotal Phase III study CLL8 showed that patients with previously-untreated chronic lymphocytic leukemia (CLL) survived their disease longer when treated with MabThera/Rituxan (rituximab) compared to chemotherapy alone. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3065471 Tue, 08 Dec 2009 06:00:00 +0100 3065471 http://www.medworm.com/index.php?rid=3065472&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-12-07.htm We kindly invite investors and analysts to participate in a conference call to discuss new clinical data and results presented during the 32nd Annual San Antonio Breast Cancer Symposium, 9-13 December 2009, San Antonio, Texas: Monday, 14 December 2009 at 17:00 CET / 8:00am PST / 16:00 GMT (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3065472 Mon, 07 Dec 2009 17:00:00 +0100 3065472 http://www.medworm.com/index.php?rid=3054837&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-12-04b.htm Roche and its development partner Biogen Idec have reported positive phase II data with ocrelizumab, a humanized anti-CD20 monoclonal antibody, in patients with relapsing-remitting multiple sclerosis (RRMS), one of the leading causes of neurological disability in young adults. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3054837 Fri, 04 Dec 2009 06:00:00 +0100 3054837 http://www.medworm.com/index.php?rid=3054836&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-12-04.htm Roche announced today that updated results of the pivotal phase III study, CLL8, will be one of many key presentations at the forthcoming 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3054836 Fri, 04 Dec 2009 06:00:00 +0100 3054836 http://www.medworm.com/index.php?rid=3046726&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-12-02.htm Roche today announced headline results from the second and third of eight T-emerge Phase III studies for taspoglutide. T-emerge 1 (subcutaneous weekly taspoglutide versus placebo in treatment-naïve patients) and T-emerge 4 (subcutaneous weekly taspoglutide versus sitagliptin versus placebo) both met their respective primary endpoints of change in HbA1c. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3046726 Wed, 02 Dec 2009 06:00:00 +0100 3046726 http://www.medworm.com/index.php?rid=3042516&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-12-01.htm We kindly invite investors and analysts to participate in a conference call to discuss new clinical data and results presented during the 2009 ASH annual meeting (The 51st Annual Meeting and Exposition of the American Society of Hematology, 5-8 December 2009, New Orleans, Louisana) (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3042516 Tue, 01 Dec 2009 17:00:00 +0100 3042516 http://www.medworm.com/index.php?rid=3025057&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-11-25.htm Roche announced today that they have filed to extend the current European label of Avastin (bevacizumab) in patients with metastatic breast cancer to allow its use in combination with a broader range of standard chemotherapies. Avastin is currently licensed in the EU as first-line treatment for patients with metastatic breast cancer in combination with paclitaxel or docetaxel. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3025057 Wed, 25 Nov 2009 06:00:00 +0100 3025057 http://www.medworm.com/index.php?rid=3014309&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-11-20b.htm Roche announced today that the Committee for Medicinal Products for Human Use (CHMP), which is responsible for conducting the initial assessment of medicinal products that have been filed for marketing authorisation in Europe, has issued a negative opinion relating to the approval of Avastin (bevacizumab) alone or in combination with irinotecan chemotherapy for the treatment of relapsed or progressive glioblastoma (GBM), the most aggressive type of primary malignant brain cancer. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3014309 Fri, 20 Nov 2009 16:45:00 +0100 3014309 http://www.medworm.com/index.php?rid=3010789&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-11-20.htm Roche announced today that ACTEMRA (tocilizumab, known as RoACTEMRA within the EU) successfully met its primary endpoint in a paediatric study of systemic onset Juvenile Idiopathic Arthritis (sJIA), by significantly improving disease signs and symptoms, a critical effectiveness measure of a sJIA treatment. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3010789 Fri, 20 Nov 2009 06:00:00 +0100 3010789 http://www.medworm.com/index.php?rid=3006421&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-11-18.htm Roche announced today that the US Food and Drug Administration (FDA) issued a complete response to Genentech, a wholly-owned member of the Roche Group, and Biogen Idec (Nasdaq: BIIB) on the companies’ applications for Rituxan/MabThera (rituximab) plus fludarabine and cyclophosphamide (FC) chemotherapy for the treatment of for the treatment of patients with previously untreated and previously treated chronic lymphocytic leukaemia (CLL). (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3006421 Wed, 18 Nov 2009 21:02:00 +0100 3006421 http://www.medworm.com/index.php?rid=3002241&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-11-18c.htm We kindly invite investors and analysts to participate in a conference call to discuss new clinical data and results presented during the 32nd Annual San Antonio Breast Cancer Symposium, 9-13 December 2009, San Antonio, Texas. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3002241 Wed, 18 Nov 2009 13:00:00 +0100 3002241 http://www.medworm.com/index.php?rid=3002242&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-11-18b.htm Roche today presented new preclinical data further supporting the differentiation of its novel cholesteryl ester transfer protein inhibitor (CETPi) dalcetrapib at this year's Scientific Sessions of the American Heart Association taking place from 14-18 November in Orlando. Based on the current safety and efficacy profile of dalcetrapib, Roche announced a new Phase III clinical trial, dal-PLAQUE 2. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=3002242 Wed, 18 Nov 2009 06:00:00 +0100 3002242 http://www.medworm.com/index.php?rid=2998019&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-11-17.htm Roche announced today that Genentech, a wholly-owned member of the Roche Group, has submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Avastin® (bevacizumab) for the treatment of women who have not received chemotherapy for advanced (metastatic) HER2-negative breast cancer (first-line treatment). One sBLA is based on the phase III AVADO study that investigated Avastin in combination with docetaxel chemotherapy. The other is based on the phase III RIBBON-1 study that investigated Avastin in combination with a taxane or anthracycline-based chemotherapy or the oral chemotherapy, Xeloda (capecitabine). (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2998019 Tue, 17 Nov 2009 06:00:00 +0100 2998019 http://www.medworm.com/index.php?rid=2998020&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-11-16.htm Roche announced today that it's RealTime ready Influenza A/H1N1 Detection Set for the 2009 H1N1 influenza virus has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA). The Roche kit detects RNA from the 2009 H1N1 influenza A virus and allows rapid and accurate identification of patients infected with this virus. It is important to differentiate patients infected with 2009 H1N1 virus from others with similar symptoms so that appropriate patient management can be commenced as early as possible. The efficacy of the Roche assay was demonstrated by clinical evaluation at worldwide study sites. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2998020 Mon, 16 Nov 2009 17:00:00 +0100 2998020 http://www.medworm.com/index.php?rid=2975932&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-11-10.htm Roche today reports results from a 320 patient phase II proof-of-concept study with it’s investigational glycine transporter-1 inhibitor RG1678. The study showed that the compound improved both the negative symptoms and the personal and social functioning of patients with schizophrenia reaching statistical significance on primary and secondary endpoints. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2975932 Tue, 10 Nov 2009 06:00:00 +0100 2975932 http://www.medworm.com/index.php?rid=2972849&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-11-09b.htm (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2972849 Mon, 09 Nov 2009 09:00:00 +0100 2972849 http://www.medworm.com/index.php?rid=2972850&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-11-09.htm Please find attached a press release issued by Chugai in Japan (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2972850 Mon, 09 Nov 2009 06:00:00 +0100 2972850 http://www.medworm.com/index.php?rid=2953089&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-10-29.htm Roche today announced that headline results from its Phase III study, T-emerge 2 (subcutaneous weekly taspoglutide versus subcutaneous twice-daily exenatide, as add-on to metformin, a thiazolidinedione [TZD], or metformin and a TZD), showed that the trial met its primary endpoint of change in HbA1c. Superiority versus exenatide was demonstrated. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2953089 Thu, 29 Oct 2009 06:00:00 +0100 2953089 http://www.medworm.com/index.php?rid=2937090&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-10-29.htm Roche today announced that headline results from its Phase III study, T-emerge 2 (subcutaneous weekly taspoglutide versus subcutaneous twice-daily exenatide, as add-on to metformin, a thiazolidinedione [TZD], or metformin and a TZD), showed that the trial met its primary endpoint of change in HbA1c. Superiority versus exenatide was demonstrated. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2937090 Thu, 29 Oct 2009 06:00:00 +0100 2937090 http://www.medworm.com/index.php?rid=2914461&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-10-22.htm Roche and Halozyme Therapeutics announced today that a new subcutaneous formulation of Herceptin using Halozyme’s Enhanze technology has entered phase III of its development. This innovative technology could allow patients with HER2-positive breast cancer to administer Herceptin for themselves with or without the support of a healthcare professional once every three weeks via a simple subcutaneous injection. Currently Herceptin, which prolongs lives of patients with this aggressive type of breast cancer, is given intravenously typically in a hospital setting at the same frequency. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2914461 Thu, 22 Oct 2009 05:00:00 +0100 2914461 http://www.medworm.com/index.php?rid=2903944&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-10-19.htm Please find attached a press release issued by Genentech and Biogen Idec in the US with respect to the approval of Rituxan in early and late stage rheumatoid arthritis in the US. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2903944 Mon, 19 Oct 2009 05:00:00 +0100 2903944 http://www.medworm.com/index.php?rid=2897153&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-10-16.htm Please find enclosed a press release by Chugai (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2897153 Fri, 16 Oct 2009 02:00:00 +0100 2897153 http://www.medworm.com/index.php?rid=2892829&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-10-15.htm Group sales up 3.1 billion to 36.4 billion Swiss francs in first nine months, an increase of 11% in local currencies (9% in Swiss francs); both divisions grow significantly faster than their respective markets; Genentech integration progressing successfully; New Group leadership appointed (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2892829 Thu, 15 Oct 2009 05:00:00 +0100 2892829 http://www.medworm.com/index.php?rid=2867718&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-10-07.htm Roche will publish its Sales Results for the 3rd Quarter of 2009 prior to the opening of the Swiss Stock Exchange on Thursday 15th October, 2009. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2867718 Wed, 07 Oct 2009 08:00:00 +0100 2867718 http://www.medworm.com/index.php?rid=2860784&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-10-05.htm Genentech, Inc., a wholly-owned member of the Roche Group yesterday announced results from two Phase III studies of Lucentis® (ranibizumab injection) in macular edema due to retinal vein occlusion (RVO), which showed, on average, patients given either of two doses of Lucentis had a clinically and statistically significant improvement in vision as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity (BCVA) at six months compared to patients receiving sham injections. Results from both trials were presented today at the Retina Congress 2009 meeting. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2860784 Mon, 05 Oct 2009 05:00:00 +0100 2860784 http://www.medworm.com/index.php?rid=2844796&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-09-30.htm Roche announced today that it has submitted a filing to the European health authorities (the European Medicines Agency) to extend the indication of RoACTEMRA to inhibit the progression of joint damage and to improve physical function in patients with rheumatoid arthritis (RA). Joint damage in RA often begins early in the disease and can lead to permanent disability, so inhibiting this structural damage to patients' joints is a critical measure of effectiveness of an RA treatment. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2844796 Wed, 30 Sep 2009 05:00:00 +0100 2844796 http://www.medworm.com/index.php?rid=2837773&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-09-25.htm Roche has been informed by the National Cancer Institute and US Eastern Cooperative Oncology Group (ECOG) that they have suspended enrollment into a phase III clinical trial (E5103) evaluating Avastin® (bevacizumab) in combination with chemotherapy in women with early-stage breast cancer based on a pre-planned cardio-toxicity analysis of the first 200 patients enrolled. The protocol for the trial specifies that enrollment be suspended if six or more cases of clinical congestive heart failure (CHF) are seen in the first 200 patients. This threshold has been met. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2837773 Fri, 25 Sep 2009 17:00:00 +0100 2837773 http://www.medworm.com/index.php?rid=2826780&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-09-24c.htm A detailed analysis of the Phase III ToGA study announced today revealed an unprecedented survival benefit for patients whose tumours exhibited a particularly high level of HER2 when Herceptin (trastuzumab) was added to standard chemotherapy (Xeloda or intravenous 5-FU and cisplatin). (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2826780 Thu, 24 Sep 2009 11:10:00 +0100 2826780 http://www.medworm.com/index.php?rid=2826781&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-09-24b.htm Roche announced the winners of its global 3Rs Award Program - a unique and innovative program that helps to reduce and limit the use of animals in preclinical research - to recognise and reward innovation and continuous improvement in animal welfare within the Roche research organisation. The award, which is now in its second year, is based on the 3Rs concept, which means Replacing animal tests where possible, Reducing the number of animals required and Refining existing scientific practices as well as animal care and husbandry. Fifteen teams of Roche scientists and animal care specialists from the companies’ global research sites in Basel, Penzberg, Nutley and Tokyo applied for awards in two categories: “Scientific Progress Fostering the 3Rs Idea” and “Laboratory A... Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2826781 Thu, 24 Sep 2009 07:00:00 +0100 2826781 http://www.medworm.com/index.php?rid=2826782&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-09-24.htm Please find enclosed a press release by Chugai (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2826782 Thu, 24 Sep 2009 05:00:00 +0100 2826782 http://www.medworm.com/index.php?rid=2822614&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-09-23d.htm Results from the ABCSG 24 trial presented today at the joint 15th ECCO and 34th ESMO 2009 congress, Berlin, Germany showed that the addition of Xeloda (capecitabine) to anthracycline- and taxane-containing regimens prior to surgery (neoadjuvant therapy) led to complete eradication of the tumour in 24% of women with HER2-positive or HER2-negative early breast cancer. The increased efficacy seen obtained by adding Xeloda was measured by an increase in the pathological complete response (pCR) rate from 16% to 24% (hazard ratio of 0.58, p=0.02). This is an important finding since the proportion of women whose tumour completely disappears when treated with standard chemotherapy for HER2-positive or HER2-negative early breast cancer is typically less than 20% (range 6–18%). (Source: Roche ... Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2822614 Wed, 23 Sep 2009 12:05:00 +0100 2822614 http://www.medworm.com/index.php?rid=2822615&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-09-23c.htm New data from several studies presented at ECCO 151 and ESMO 342 confirm unique benefits of Avastin (bevacizumab) and Xeloda (capecitabine) in treatment of colon cancer (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2822615 Wed, 23 Sep 2009 12:00:00 +0100 2822615 http://www.medworm.com/index.php?rid=2822616&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-09-23b.htm New data from phase II Avastin study and a phase I extension study of highly selective BRAF inhibitor (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2822616 Wed, 23 Sep 2009 09:15:00 +0100 2822616 http://www.medworm.com/index.php?rid=2822617&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-09-23a.htm Key data from four presentations at the joint ECCO 15 and ESMO 34 congress strongly support the clinical benefit of Avastin in advanced non-small cell lung cancer (NSCLC) (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2822617 Wed, 23 Sep 2009 07:00:00 +0100 2822617 http://www.medworm.com/index.php?rid=2813675&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-09-21b.htm We are pleased to invite you to a Conference Call to discuss new data on Roche’s oncology products and pipeline being presented during the joint 15th Congress of the European Cancer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO), which runs from September 20th – September 24th, 2009 in Berlin, Germany. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2813675 Mon, 21 Sep 2009 08:00:00 +0100 2813675 http://www.medworm.com/index.php?rid=2813676&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-09-21.htm Nearly 150 abstracts covering new tumour types, new patient groups and existing indications to feature in ECCO-ESMO program Roche will present encouraging results from nearly 150 scientific studies investigating use of its major cancer medicines at ECCO 15 ESMO 34, which opens in Berlin, Germany today. Overall survival benefits will be demonstrated for Avastin (bevacizumab) in malignant melanoma and for Herceptin (trastuzumab) in gastric cancer. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2813676 Mon, 21 Sep 2009 05:00:00 +0100 2813676 http://www.medworm.com/index.php?rid=2806228&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-09-18.htm Application for Approval of Additional Indication of Pancreatic Cancer (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2806228 Fri, 18 Sep 2009 08:05:00 +0100 2806228 http://www.medworm.com/index.php?rid=2802675&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-09-17.htm Results show patients treated with MabThera as initial and follow-on therapy stay in remission for longer. Roche announced today results from the international phase III study PRIMA1, which show that MabThera (rituximab) maintenance therapy can significantly increase the time until the disease progresses in newly-treated patients with advanced follicular lymphoma, a common and slow-developing but incurable form of lymphoma. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2802675 Thu, 17 Sep 2009 05:00:00 +0100 2802675 http://www.medworm.com/index.php?rid=2792124&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-09-14.htm Roche will publish its Sales Results for the 3rd Quarter of 2009 prior to the opening of the Swiss Stock Exchange on Thursday 15th October, 2009. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2792124 Mon, 14 Sep 2009 12:00:00 +0100 2792124 http://www.medworm.com/index.php?rid=2784365&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-09-11.htm We are pleased to invite you to a Conference Call to discuss new data on Roche’s oncology products and pipeline being presented during the joint 15th Congress of the European Cancer Organisation (ECCO) and 34th Congress of the European Society for Medical Oncology (ESMO), which runs from September 20th – September 24th, 2009 in Berlin, Germany. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2784365 Fri, 11 Sep 2009 08:00:00 +0100 2784365 http://www.medworm.com/index.php?rid=2773762&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-09-08.htm William M. Burns, Juergen Schwiezer and Jonathan Knowles to retire – Pascal Soriot appointed COO Pharma Division and Daniel O’Day appointed COO Diagnostics Division – Jean-Jacques Garaud and Dan Zabrowski to become Members of Enlarged Executive Committee – Ian Clark appointed CEO Genentech (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2773762 Tue, 08 Sep 2009 05:00:00 +0100 2773762 http://www.medworm.com/index.php?rid=2760521&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-09-03b.htm Roche (SIX: RO, ROG; OTCQX: RHHBY) has been rated as the new Super Sector Leader in Healthcare on the Dow Jones Sustainability Index, placing Roche as the most sustainable healthcare company worldwide. Selection into the global Dow Jones Sustainability World Index as well as the pan-European Dow Jones STOXX Sustainability Index follows a thorough analysis of corporate economic, environmental and social performance, and takes into account elements such as corporate governance, risk management, access to medicines, climate change, supply chain standards, stakeholder engagement and labor practice. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2760521 Thu, 03 Sep 2009 09:00:00 +0100 2760521 http://www.medworm.com/index.php?rid=2750282&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fcobas701_200px.jpg Roche announced today that the CE Mark certification for cobas 8000 modular analyzer series has been granted allowing commercial distribution of the first analyzers in Europe as well as in all countries recognizing the CE Mark in the EMEA, Latin America and Asia-Pacific regions. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2750282 Tue, 01 Sep 2009 05:00:00 +0100 2750282 http://www.medworm.com/index.php?rid=2746945&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-08-31b.htm Plus new oral solution offers dosing flexibility for pediatric patients. Roche announced today that the U.S. Food and Drug Administration (FDA) has approved Valcyte (valganciclovir hydrochloride) for the prevention of cytomegalovirus (CMV) disease in pediatric kidney and heart transplant patients (4 months to 16 years of age) at high risk of developing CMV disease. The FDA also approved a new pediatric oral solution formulation for Valcyte, which will allow easier administration to pediatric patients 4 months to 16 years of age. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2746945 Mon, 31 Aug 2009 05:01:00 +0100 2746945 http://www.medworm.com/index.php?rid=2746946&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-08-31.htm Roche and Lonza announced today that Genentech Singapore Pte. Ltd. (“Genentech Singapore”), a wholly-owned member of the Roche Group, elected to exercise an option to purchase from Lonza its cell culture biologic manufacturing facility in Singapore. The facility, which is mechanically complete, will be merged with Genentech Singapore's existing biologic manufacturing facility. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2746946 Mon, 31 Aug 2009 05:00:00 +0100 2746946 http://www.medworm.com/index.php?rid=2707199&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-cor-50336_avastin_200px.jpg Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that a Phase III study of Avastin (bevacizumab) in combination with a range of chemotherapies met its primary endpoint of increasing the time women with previously treated advanced HER2 negative breast cancer lived without the disease getting worse (progression-free survival or PFS) compared to chemotherapy alone. In the RIBBON-2 study, investigators chose the type of chemotherapy used in combination with Avastin and the chemotherapies were assessed together in the primary endpoint analysis. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2707199 Tue, 18 Aug 2009 05:00:00 +0100 2707199 http://www.medworm.com/index.php?rid=2669503&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-rochecontinents-200px.gif For the third time, Roche and the Salzburg Festival have invited 100 students to take part in "Roche Continents". Students of science, music and the fine arts from 21 European countries will be spending a week together in Salzburg discussing the topic of creativity in their fields of study and uncovering the common ground in what at first glance seem to be very different disciplines. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2669503 Wed, 05 Aug 2009 08:00:00 +0100 2669503 http://www.medworm.com/index.php?rid=2663500&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-08-03.htm Roche today announced that the U.S. Food and Drug Administration (FDA) has approved Avastin (bevacizumab) plus interferon alpha for people with metastatic renal cell carcinoma, the most common type of kidney cancer. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2663500 Mon, 03 Aug 2009 05:00:00 +0100 2663500 http://www.medworm.com/index.php?rid=2659574&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-08-01.htm Roche today announced that patients with advanced non-small cell lung cancer (NSCLC) who received Tarceva (erlotinib) immediately after initial chemotherapy in SATURN, a pivotal Phase III study, had a significant, 23% improvement in overall survival (hazard ratio =0.81; p-value=0.0088) compared to patients who received placebo. As previously announced, the safety results in this study were consistent with what has been seen before and there were no new or unexpected safety signals. Overall survival was a key secondary endpoint of the study and these new survival data were presented during the ongoing 13th World Conference on Lung Cancer being held in San Francisco. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2659574 Sat, 01 Aug 2009 05:00:00 +0100 2659574 http://www.medworm.com/index.php?rid=2655733&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-07-31.htm Roche announced today that the U.S. Food & Drug Administration (FDA) has accepted the resubmission for the ACTEMRA (tocilizumab) Biologics License Application (BLA), following the company’s receipt of a complete response in September 2008. The FDA has designated a Class II, or six-month, review timeline for the resubmission, according to Prescription Drug User Fee Act (PDUFA) guidelines. ACTEMRA is the first interleukin-6 (IL-6) receptor-inhibiting monoclonal antibody for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA). (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2655733 Fri, 31 Jul 2009 06:00:00 +0100 2655733 http://www.medworm.com/index.php?rid=2655734&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-07-30.htm Roche announced today that the Phase III study CRUISE showed Lucentis (ranibizumab injection) improved vision in patients with swelling in the retina (macular edema) due to central retinal vein occlusion (RVO). (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2655734 Thu, 30 Jul 2009 16:00:00 +0100 2655734 http://www.medworm.com/index.php?rid=2647552&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-07-29.htm More patients with advanced breast cancer could benefit from Avastin as a result of a broader label allowing Avastin to be combined with both docetaxel or paclitaxel chemotherapy, Roche announced today. In March 2007, Avastin was approved in Europe for the first-line treatment of patients with advanced breast cancer, in combination with paclitaxel. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2647552 Wed, 29 Jul 2009 05:00:00 +0100 2647552 http://www.medworm.com/index.php?rid=2647553&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-07-28c.htm Genentech, Inc., a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the appointment of Sandra J. Horning, M.D., to senior vice president, global head, Clinical Development Hematology/Oncology. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2647553 Tue, 28 Jul 2009 16:15:00 +0100 2647553 http://www.medworm.com/index.php?rid=2647554&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-07-28b.htm Roche Applied Science and Google.org recently started a joint project to demonstrate the feasibility of developing a multidisciplinary surveillance, research and response system. This system will enhance the ability to predict and prevent emerging infectious diseases in East Africa. Roche has donated a Genome Sequencer FLX system as backbone of this project.“We are proud to work with Google.org, and the dedicated research organizations in Kenya to bring this technology to a region of the world where novel viruses frequently emerge. We are confident that access to the 454 Sequencing Systems will improve monitoring of novel infectious diseases and enable faster discovery in case of an outbreak,” said Chris McLeod, CEO of 454 Life Sciences, a member of the Roche Group. (Source: Ro... Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2647554 Tue, 28 Jul 2009 12:00:00 +0100 2647554 http://www.medworm.com/index.php?rid=2636668&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-actemra43-200px.jpg Roche announced today that the European Union’s Committee on Human Medicinal Products (CHMP) has issued a positive recommendation for the use of MabThera (rituximab) in patients with relapsed or refractory chronic lymphocytic leukaemia (CLL). Physicians will soon be able to prescribe MabThera, the first monoclonal antibody therapy approved for previously untreated CLL, in combination with chemotherapy to patients who have been treated for the disease but whose cancer has returned or have not appropriately responded to therapy. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2636668 Fri, 24 Jul 2009 09:30:00 +0100 2636668 http://www.medworm.com/index.php?rid=2632692&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-07-24.htm Following the publication of Chugai’s official 2009 interim results, Roche offers this investor update which reconciles these results with the results for Chugai published by Roche as part of the Roche Group’s 2009 interim results. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2632692 Fri, 24 Jul 2009 06:00:00 +0100 2632692 http://www.medworm.com/index.php?rid=2628575&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-07-23.htm Integration of Genentech progressing rapidly; full-year outlook raised; Group sales up 2 billion to 24 billion Swiss francs, an increase of 10% in local currencies (9% in Swiss francs); both divisions grow significantly faster than their respective markets. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2628575 Thu, 23 Jul 2009 05:00:00 +0100 2628575 http://www.medworm.com/index.php?rid=2624100&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-07-22.htm Roche will publish its Half Year Results for 2009 prior to the opening of the Swiss Stock Exchange on July 23 at 7.00 CET / 6.00 GMT / 1.00 AM EDT / 22.00 PM PDT (evening before). Concurrently, the Half Year Presentation Slides and the Half Year Report will be available on the Roche website (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2624100 Wed, 22 Jul 2009 08:00:00 +0100 2624100 http://www.medworm.com/index.php?rid=2624101&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-07-22b.htm Please find enclosed a press release by Chugai. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2624101 Wed, 22 Jul 2009 06:05:00 +0100 2624101 http://www.medworm.com/index.php?rid=2624102&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-07-21.htm Roche Diagnostics is featuring a diverse portfolio of solutions designed to help healthcare facilities and reference labs do more with less and enhance patient care in booth #1331 at the AACC/CSCC 2009 Clinical Lab Expo here, July 21-23. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2624102 Tue, 21 Jul 2009 13:00:00 +0100 2624102 http://www.medworm.com/index.php?rid=2616269&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-07-20.htm Roche announced today results from the international phase III study NO16968 (XELOXA), investigating oral Xeloda in combination with intravenous oxaliplatin (XELOX) immediately after surgery, which show that patients with colon cancer taking XELOX live disease free for longer compared to those taking the commonly used intravenous chemotherapy combination 5-fluorouracil/leucovorin (5-FU/LV). The data prove that XELOX is superior to 5-FU/LV in terms of the time patients live without their cancer being detectable. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2616269 Mon, 20 Jul 2009 05:00:00 +0100 2616269 http://www.medworm.com/index.php?rid=2593991&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-07-13.htm Roche announced today that SATURN, a pivotal Phase III study, met a key secondary endpoint of extending overall survival in patients with advanced non-small cell lung cancer (NSCLC) who received Tarceva® (erlotinib) immediately after their initial chemotherapy. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2593991 Mon, 13 Jul 2009 05:00:00 +0100 2593991 http://www.medworm.com/index.php?rid=2566743&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-07-02.htm Roche announced today that the Phase III study BRAVO showed Lucentis (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in patients with macular edema due to branch retinal vein occlusion. The safety profile of Lucentis was consistent with previous experience and no new adverse events related to Lucentis were observed in the study. Retinal vein occlusion (RVO) is a common cause of vision loss that occurs when blood flow through a retinal vein becomes blocked, such as by a blood clot. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2566743 Thu, 02 Jul 2009 16:00:00 +0100 2566743 http://www.medworm.com/index.php?rid=2558607&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-tamiflu-34345_200px.jpg Roche today announced the initiation of the Tamiflu Reserves Program (TRP) for developing economies. The program, which is effective immediately, will serve to ensure that Tamiflu (oseltamivir) is available to many governments and patients in developing nations for use when the World Health Organization (WHO) has declared an influenza pandemic, or for the management of a novel influenza strain defined by WHO that has significant and current pandemic potential. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2558607 Wed, 01 Jul 2009 05:00:00 +0100 2558607 http://www.medworm.com/index.php?rid=2519613&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-06-26b.htm Physicians will be able to offer patients more Avastin-based treatment options. Patients with advanced (metastatic) breast cancer will be able to benefit from treatment with Avastin (bevacizumab) as a result of a new broader label recommendation in Europe, Roche announced today. The positive opinion issued by the European Committee for Medicinal Products for Human Use (CHMP) is for the use of Avastin in combination with paclitaxel or docetaxel chemotherapy for the first-line treatment of patients with metastatic breast cancer. Avastin was granted European approval for use in combination with paclitaxel in metastatic breast cancer in March 2007. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2519613 Fri, 26 Jun 2009 14:00:00 +0100 2519613 http://www.medworm.com/index.php?rid=2516416&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-06-26.htm Roche announced today that it has submitted a combined filing to the European health authorities (the European Medicines Agency) for three new indications to extend the label for MabThera to use as a first-line biologic therapy for patients with rheumatoid arthritis (RA). The new filings are for patients who have not been treated with methotrexate (MTX), the current standard treatment option; those who have had an inadequate response to MTX; and for the prevention of joint damage across all RA patient populations. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2516416 Fri, 26 Jun 2009 05:00:00 +0100 2516416 http://www.medworm.com/index.php?rid=2494173&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-06-23.htm Roche will publish its Half Year Results for 2009 prior to the opening of the Swiss Stock Exchange on July 23 at 7.00 CET / 6.00 GMT / 1.00 AM EDT / 22.00 PM PDT (evening before). (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2494173 Tue, 23 Jun 2009 08:00:00 +0100 2494173 http://www.medworm.com/index.php?rid=2481854&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-06-11.htm RA patients with enhanced response identified. New data show for the first time that a course of 2 infusions of MabThera 1000mg (rituximab, known as Rituxan within the United States) given every 24 weeks as the patient’s first biologic can significantly slow down joint damage following 1 year of treatment, with virtually no progression of joint damage seen from six months. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2481854 Thu, 11 Jun 2009 08:15:00 +0100 2481854 http://www.medworm.com/index.php?rid=2481855&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-06-11b.htm We are pleased to invite you to a Conference Call to discuss new data on our Rheumatoid Arthritis portfolio being presented during the 2009 EULAR Conference (European League Against Rheumatism), which runs from June 10th – June 13th, 2009 in Copenhagen, Denmark. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2481855 Thu, 11 Jun 2009 08:00:00 +0100 2481855 http://www.medworm.com/index.php?rid=2481856&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-06-11a.htm We are pleased to invite you to an accounting conference call followed by Q&A on the impact of the Genentech transaction on the Roche Group’s consolidated equity. As previously announced, this call will focus on prime accounting implications in order to provide an appropriate baseline for analyst models. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2481856 Thu, 11 Jun 2009 05:00:00 +0100 2481856 http://www.medworm.com/index.php?rid=2481857&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-06-10.htm Up to 56% of patients with active rheumatoid arthritis (RA) treated with ACTEMRA (tocilizumab, known as RoACTEMRA within the EU) for over two years, will achieve disease remission, according to new data presented today at the European League Against Rheumatism (EULAR) congress. Remission, as defined by DAS28 <2.62, provides real-life benefits to people living with RA by meaningfully improving disease symptoms which help them to continue or regain normal day-to-day functioning. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2481857 Tue, 09 Jun 2009 22:01:00 +0100 2481857 http://www.medworm.com/index.php?rid=2466362&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-06-09.htm Roche today announced it will start Phase III clinical investigations for aleglitazar, its innovative PPAR co-agonist R1439 which is uniquely designed to reduce cardiovascular morbidity and mortality in high risk patients with type 2 diabetes. This decision is supported by data from the Phase II SYNCHRONY study published today in The Lancet and announced at the American Diabetes Association (ADA) in New Orleans, US. The phase III programme is anticipated to start in the second half of 2009. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2466362 Tue, 09 Jun 2009 05:00:00 +0100 2466362 http://www.medworm.com/index.php?rid=2466363&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-06-08.htm We are pleased to invite you to an accounting conference call followed by Q&A on the impact of the Genentech transaction on the Roche Group’s consolidated equity. As previously announced, this call will focus on prime accounting implications in order to provide an appropriate baseline for analyst models. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2466363 Mon, 08 Jun 2009 08:00:00 +0100 2466363 http://www.medworm.com/index.php?rid=2461391&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-06-05.htm We kindly invite investors and analysts to participate in a conference call that will be held during the American Diabetes Association (ADA) 69th Scientific Sessions in New Orleans. On the call, Roche will discuss new phase II data on its PPAR co-agonist aleglitazar (R1439). Further, Roche will provide an overall update on its pipeline and emerging franchise in diabetes and metabolic diseases. The presentation will be followed by a Q&A session. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2461391 Fri, 05 Jun 2009 08:30:00 +0100 2461391 http://www.medworm.com/index.php?rid=2450982&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-06-02.htm New Phase III study results presented for the first time today at the ninth annual American Transplant Congress 2009 (ATC) demonstrate that doubling the duration of preventive therapy (‘prophylaxis’) with Valcyte (oral valganciclovir), significantly reduces the incidence of CMV disease by 56% in high-risk kidney transplant patients within the first year post-transplant. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2450982 Tue, 02 Jun 2009 05:00:00 +0100 2450982 http://www.medworm.com/index.php?rid=2450983&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-06-01.htm Roche announced today results from a phase I study with PLX4032 (R7204) a new, highly selective and promising treatment for patients with advanced melanoma whose cancer harbours the BRAF mutation (known as mutation-positive). Patients treated with PLX4032 lived for a median of at least six months without their disease getting worse and experienced shrinkage of their tumours; this included patients where the cancer had spread to the liver, lung and bone. Historically, metastatic melanoma patients live less than two months before their disease progresses. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2450983 Mon, 01 Jun 2009 10:30:00 +0100 2450983 http://www.medworm.com/index.php?rid=2450984&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-05-31.htm Data from the ToGA study presented today at the American Society for Clinical Oncology Annual Meeting in Orlando, Florida showed that adding Herceptin (trastuzumab) to standard chemotherapy (Xeloda or intravenous 5-FU and cisplatin) prolongs the lives of patients with this aggressive cancer on average by nearly three months to 13.8 months. Advanced stomach (gastric) cancer is associated with a poor prognosis; the median survival time after diagnosis is approximately 10 months with currently available therapies. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2450984 Sun, 31 May 2009 14:30:00 +0100 2450984 http://www.medworm.com/index.php?rid=2444713&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-05-30b.htm Roche today announced that a Phase III study (ATLAS) showed patients with advanced non-small cell lung cancer (NSCLC) who received Tarceva® (erlotinib) in combination with Avastin® (bevacizumab) as first-line maintenance treatment had a 39 percent improvement in the time they lived without the disease advancing (progression-free survival or PFS), compared with those who received Avastin plus placebo (hazard ratio=0.72; p=0.0012). Adverse events were consistent with previous Avastin or Tarceva NSCLC studies, or trials evaluating the two medicines together. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2444713 Sat, 30 May 2009 15:00:00 +0100 2444713 http://www.medworm.com/index.php?rid=2444714&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-05-30.htm Results suggest future trials may hold promise for Avastin as early-stage colon cancer treatment even though C-08 study does not meet primary endpoint (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2444714 Sat, 30 May 2009 13:00:00 +0100 2444714 http://www.medworm.com/index.php?rid=2438238&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-05-28.htm Final results from a phase II study presented at ASCO show that 25% of women with advanced HER2-positive breast cancer experienced remarkable shrinkage of their tumours, when treated with a new agent called trastuzumab-DM1 (T-DM1). (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2438238 Thu, 28 May 2009 05:00:00 +0100 2438238 http://www.medworm.com/index.php?rid=2438239&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-05-27.htm Phase II data on PPAR co-agonist aleglitazar and overall update on Roche´s diabetes & metabolic diseases pipeline (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2438239 Wed, 27 May 2009 08:00:00 +0100 2438239 http://www.medworm.com/index.php?rid=2435205&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-05-26.htm We are pleased to invite you to a Conference Call to discuss new data on our Rheumatoid Arthritis portfolio being presented during the 2009 EULAR Conference (European League Against Rheumatism), which runs from June 10th – June 13th, 2009 in Copenhagen, Denmark. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2435205 Tue, 26 May 2009 09:30:00 +0100 2435205 http://www.medworm.com/index.php?rid=2435206&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-05-25b.htm We are pleased to invite you to two analyst briefings to discuss data presented on the Roche Group’s oncology products and pipeline at the American Society of Clinical Oncology meeting (ASCO) in Orlando (May 29 – June 2, 2009). (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2435206 Mon, 25 May 2009 08:01:00 +0100 2435206 http://www.medworm.com/index.php?rid=2432946&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-05-25.htm Roche announced today that new two-year data from the LITHE study demonstrate that ACTEMRA (tocilizumab, known as RoACTEMRA within the EU) continues to be highly effective at inhibiting joint structural damage and maintaining consistently high remission rates. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2432946 Mon, 25 May 2009 05:00:00 +0100 2432946 http://www.medworm.com/index.php?rid=2425704&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-05-20.htm Roche and Genentech will present a large number of abstracts on their broad oncology portfolio at the Annual Meeting of American Society of Clinical Oncology (ASCO) in Orlando on May 29 – June 2. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2425704 Wed, 20 May 2009 08:00:00 +0100 2425704 http://www.medworm.com/index.php?rid=2420307&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-05-19b.htm Genentech, Inc., wholly owned member of the Roche Group (SWX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB) today announced that the companies submitted two supplemental Biologics License Applications (sBLAs) to the U.S. Food and Drug Administration (FDA) for Rituxan (rituximab) plus standard chemotherapy for people with previously untreated or treated chronic lymphocytic leukemia (CLL). (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2420307 Tue, 19 May 2009 20:00:00 +0100 2420307 http://www.medworm.com/index.php?rid=2420308&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-05-19.htm We are pleased to invite you to two analyst briefings to discuss data presented on the Roche Group’s oncology products and pipeline at the American Society of Clinical Oncology meeting (ASCO) in Orlando (May 29 – June 2, 2009). (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2420308 Tue, 19 May 2009 14:00:00 +0100 2420308 http://www.medworm.com/index.php?rid=2420309&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-05-18.htm Today, Roche opened the Joint Science & Technology Laboratory in Basel, where Roche Pharma scientists are using the innovative xCELLigence real-time Cell Analyzer system of Roche Diagnostics to investigate hepatic and cardiac toxicities in vitro. This new technology will improve the predictive value of in vitro assessments of organ toxicity and help to reduce animal testing in toxicity research. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2420309 Mon, 18 May 2009 12:30:00 +0100 2420309 http://www.medworm.com/index.php?rid=2409801&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-05-15b.htm Data from RIBBON 1 study provides efficacy and safety information with different types of chemotherapy (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2409801 Thu, 14 May 2009 22:05:00 +0100 2409801 http://www.medworm.com/index.php?rid=2409803&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-05-15.htm More than 500 scientific abstracts to be presented across 20 types of cancers. Results could significantly improve the way cancer is treated for patients with inoperable stomach cancer; advanced melanoma; lung and breast cancers. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2409803 Thu, 14 May 2009 22:00:00 +0100 2409803 http://www.medworm.com/index.php?rid=2409805&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-05-11b.htm Phase II data on PPAR co-agonist aleglitazar and overall update on Roche's diabetes & metabolic diseases pipeline (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2409805 Mon, 11 May 2009 08:00:00 +0100 2409805 http://www.medworm.com/index.php?rid=2394365&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Fmed-avastin-0050343-200px.jpg Roche today announced that the US Food and Drug Administration (FDA) granted accelerated approval of Avastin (bevacizumab) for people with glioblastoma with progressive disease following prior therapy. The new indication for Avastin was granted under the FDA’s accelerated approval program that allows provisional approval of medicines for cancer or other life-threatening diseases. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2394365 Wed, 06 May 2009 05:00:00 +0100 2394365 http://www.medworm.com/index.php?rid=2394366&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-05-04.htm We are pleased to invite you to two analyst briefings to discuss data presented on the Roche Group’s oncology products and pipeline at the American Society of Clinical Oncology meeting (ASCO) in Orlando (May 29 – June 2, 2009). (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2394366 Mon, 04 May 2009 12:00:00 +0100 2394366 http://www.medworm.com/index.php?rid=2378804&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-04-30.htm Roche tonight confirms that it has been in contact with the World Health Organization (WHO) following the announcement to move to influenza pandemic alert phase 5. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2378804 Thu, 30 Apr 2009 07:30:00 +0100 2378804 http://www.medworm.com/index.php?rid=2372030&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-04-27.htm Roche (SWX: RO, ROG; OTCQX: RHHBY), InterMune, Inc. (Nasdaq: ITMN) and Pharmasset (Nasdaq: VRUS) announced the first results from their innovative, interferon-free regimen of direct-acting antiviral (DAA) combination therapy for the treatment of patients chronically infected with the hepatitis C virus (HCV). The study combined two oral DAAs, R7227 (also known as ITMN-191) and R7128, for the first time in patients. There were no serious adverse events reported during the 14 days of dosing, the reductions in levels of HCV RNA were significant. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2372030 Mon, 27 Apr 2009 05:00:00 +0100 2372030 http://www.medworm.com/index.php?rid=2355530&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-04-22.htm Roche today announced the results of the first phase III trial evaluating the use of Avastin (bevacizumab) plus chemotherapy (FOLFOX) for the treatment of colon cancer immediately following surgery (adjuvant therapy) compared to chemotherapy alone. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2355530 Wed, 22 Apr 2009 05:00:00 +0100 2355530 http://www.medworm.com/index.php?rid=2336296&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-04-16.htm Genentech transaction completed, integration proceeding rapidly (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2336296 Thu, 16 Apr 2009 05:00:00 +0100 2336296 http://www.medworm.com/index.php?rid=2336297&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-04-15b.htm Roche will publish its Sales Results for the 1st Quarter of 2009 prior to the opening of the Swiss Stock Exchange on Thursday 16th April, 2009. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2336297 Wed, 15 Apr 2009 08:00:00 +0100 2336297 http://www.medworm.com/index.php?rid=2336298&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-04-15.htm Roche today announced that it will join forces with Novo Nordisk and the World Diabetes Foundation (WDF) in Novo Nordisk’s five-year program called “Changing Diabetes in Children”. Roche Diabetes Care will actively endorse humanitarian activities in this project which is starting in Tanzania, Uganda, Cameroon, Guinea-Conakry and the Democratic Republic of Congo. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2336298 Wed, 15 Apr 2009 06:45:00 +0100 2336298 http://www.medworm.com/index.php?rid=2336299&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-04-14.htm Following the completion of the Genentech transaction Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) today announced the successful start of the integration. Building on the long-standing and trustful relationship of the two companies, senior leaders from Genentech and Roche have made considerable progress in a short period of time to set the course for the integration. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2336299 Tue, 14 Apr 2009 21:00:00 +0100 2336299 http://www.medworm.com/index.php?rid=2313877&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-04-08.htm Roche and Genentech, Inc. announced today a phased voluntary withdrawal of the psoriasis drug Raptiva (efalizumab) from the U.S. market. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2313877 Wed, 08 Apr 2009 20:30:00 +0100 2313877 http://www.medworm.com/index.php?rid=2313878&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-04-07.htm As announced earlier, the Roche Group will publish its first quarter sales results on 16 April 2009. To reflect the Pharmaceuticals Division’s integrated organisation following the buy-out of Genentech non-controlling interests, the Pharmaceuticals Division’s results will in future be reported by region and not by sub-division as previously. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2313878 Tue, 07 Apr 2009 05:00:00 +0100 2313878 http://www.medworm.com/index.php?rid=2313879&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-04-02.htm Roche announced today that its new LightCycler test for the detection of methicillin-resistant Staphylococcus aureus (MRSA) is now available with the CE Mark, allowing it to be sold for clinical use in the European Union. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2313879 Thu, 02 Apr 2009 05:00:00 +0100 2313879 http://www.medworm.com/index.php?rid=2313880&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-04-01.htm Genentech, Inc. announced today that the U.S. Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) voted unanimously that the response seen with Avastin (bevacizumab) in people with previously treated glioblastoma is of sufficient magnitude to be reasonably likely to predict clinical benefit. The FDA is expected to make a decision whether to grant accelerated approval of Avastin for use in this most aggressive form of brain cancer by May 5, 2009. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2313880 Wed, 01 Apr 2009 05:30:00 +0100 2313880 http://www.medworm.com/index.php?rid=2313881&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-03-31.htm The European Medicines Agency (EMEA) has removed a restriction in the product label which prevented the use of Avastin (bevacizumab) in some patients whose primary cancer has spread to their brain (brain metastases). (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2313881 Tue, 31 Mar 2009 15:30:00 +0100 2313881 http://www.medworm.com/index.php?rid=2313882&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-03-26b.htm Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) and Genentech announced today that Roche has completed its acquisition of Genentech pursuant to a short-form merger in which Genentech became a wholly-owned member of the Roche Group. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2313882 Thu, 26 Mar 2009 16:30:00 +0100 2313882 http://www.medworm.com/index.php?rid=2290626&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-03-26.htm Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) announced today that its wholly-owned subsidiary, Roche Investments USA Inc., completed its tender offer for the publicly held shares of Genentech (NYSE: DNA). The offer expired at midnight, New York City time, at the end of Wednesday, March 25. A total of approximately 395.7 million shares of Genentech common stock were tendered representing 84.7% of Genentech’s publicly held shares. Roche Investments USA Inc. has accepted for payment all shares validly tendered pursuant to its tender offer. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2290626 Thu, 26 Mar 2009 06:00:00 +0100 2290626 http://www.medworm.com/index.php?rid=2290627&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-03-24.htm Roche (SWX: ROG.VX; RO.S, OTCQX: RHHBY) announced today that RiskMetrics Group, Inc., a leading provider of risk and corporate governance services to participants in the global financial markets, recommends that Genentech (NYSE: DNA) shareholders tender their shares to Roche at $95.00 per share. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2290627 Tue, 24 Mar 2009 16:30:00 +0100 2290627 http://www.medworm.com/index.php?rid=2279607&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-03-19.htm Today, Roche submitted an extension of the Marketing Authorisation Application to the European Medicines Agency (EMEA) for the use of Tarceva (erlotinib) as a first-line maintenance treatment - immediately following initial treatment with platinum-based chemotherapy - for patients with advanced non-small cell lung cancer (NSCLC) who have not progressed in their disease. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2279607 Thu, 19 Mar 2009 06:00:00 +0100 2279607 http://www.medworm.com/index.php?rid=2279608&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-03-18b.htm Roche will publish its Sales Results for the 1st Quarter of 2009 prior to the opening of the Swiss Stock Exchange on Thursday 16th April, 2009. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2279608 Wed, 18 Mar 2009 09:00:00 +0100 2279608 http://www.medworm.com/index.php?rid=2279609&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-03-18.htm Roche today announced results from a major international study which show that adding Herceptin (trastuzumab) to standard chemotherapy significantly prolongs lives of patients with HER2-positive stomach (gastric) cancer. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2279609 Wed, 18 Mar 2009 06:00:00 +0100 2279609 http://www.medworm.com/index.php?rid=2265563&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-03-12.htm Roche (SWX: ROG.VX; RO.S) and Genentech (NYSE: DNA) announced today that they signed a merger agreement under which Roche will acquire the outstanding publicly held interest in Genentech for US$95.00 per share in cash, or a total payment of approximately US$46.8 billion to equity holders of Genentech other than Roche. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2265563 Thu, 12 Mar 2009 06:00:00 +0100 2265563 http://www.medworm.com/index.php?rid=2253521&cid=s_37969_34_f&fid=37969&url=http%3A%2F%2Fwww.roche.com%2Fen%2Finvestors%2Fir_update%2Finv-update-2009-03-11.htm The Breast International Group (BIG) in collaboration with Roche announced today that women with HER2 positive early breast cancer continue to benefit from Herceptin (trastuzumab) several years after treatment completion and as a result enjoy a longer life disease free. The patients were treated for one year with Herceptin and followed up for four years. These data from the HERA study were presented at the Primary Therapy in Early Breast Cancer conference in St. Gallen, Switzerland. (Source: Roche Investor Update) Roche Investor Update organizations http://www.medworm.com/rss/comments.php?id=2253521 Wed, 11 Mar 2009 06:00:00 +0100 2253521